Featured Research

from universities, journals, and other organizations

The Fabled Myrrh May Fight Cholesterol

Date:
October 25, 2000
Source:
University Of Pennsylvania Medical Center
Summary:
The extract from a tree in the fabled myrrh family is being investigated by researchers at the University of Pennsylvania School of Medicine for properties that may lower cholesterol.

The extract from a tree in the fabled myrrh family is being investigated by researchers at the University of Pennsylvania School of Medicine for properties that may lower cholesterol.

Dr. Philippe Szapary, Assistant Professor of Medicine at Penn who writes frequently about the use of alternative medicine in treating cardiovascular disease, is in the midst of a study of the dietary supplement gugulipid, an extract from the gummy resin of the thorny mukul myrrh bush of western India that has made its way into American health-food stores.

The bitter-tasting, fragrant myrrh is used in incense and perfumes – in the Christian tradition, a form of sweet-scented myrrh was presented by the three wise men to the infant Jesus – and the mukul myrrh, specifically, has a 2,000-year history in traditional Indian medicine. Ayurvedic health practitioners, who combine meditation, yoga and diet to address physical illness, use the resin extract in treating artherosclerosis, obesity and arthritis.

In the 1960s and ‘70s, Indian scientists were able to identify two properties of the extract – which, combined, they named gugulipid -- that appeared to aid in lowering cholesterol.

“This is something that’s been around for thousands of years, and when some scientists looked into it, they actually found a scientific basis for its effectiveness,” said Szapary. “But there’s still not enough documentation. We’re trying, in a methodical way, to establish that basis.” His work has been recognized by the National Center for Complementary and Alternative Medicine (NCCAM), which recently awarded him a five-year research grant of about $150,000 for each year.

“In this country, supplements such as gugulipid are regarded as ‘herbs’ rather than drugs, which means they aren’t currently regulated by the Food and Drug Administration,” Szapary said. “My interest is to gather enough evidence to demonstrate whether a gugulipid extract is safe and effective, in the short term, for use by Americans with mild-to-moderately elevated cholesterol.” His work with gugulipid, which began last spring, is designed to assess the drug through a simple, randomized study using 90 subjects.

Participants are divided into three groups; the first is administered a placebo, the second a standard dosage of gugulipid, and the third a higher dosage of the supplement. Each participant remains on the regimen for two months while blood tests indicate its effectiveness. Thus far 60 people have taken part.

“The participants have uniformly felt like they’ve been able to tolerate the medicine with few side effects,” he said. The study -- which began prior to Szapary’s grant from the NCCAM -- is funded in part by the General Clinical Research Center at Penn, which, in turn, is funded by the National Institutes of Health, and by the Sabinsa Corp., a manufacturer of gugulipid.

Editor’s note: Dr. Szapary has no financial interest in the Sabinsa corporation.


Story Source:

The above story is based on materials provided by University Of Pennsylvania Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Pennsylvania Medical Center. "The Fabled Myrrh May Fight Cholesterol." ScienceDaily. ScienceDaily, 25 October 2000. <www.sciencedaily.com/releases/2000/10/001025072356.htm>.
University Of Pennsylvania Medical Center. (2000, October 25). The Fabled Myrrh May Fight Cholesterol. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2000/10/001025072356.htm
University Of Pennsylvania Medical Center. "The Fabled Myrrh May Fight Cholesterol." ScienceDaily. www.sciencedaily.com/releases/2000/10/001025072356.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins